Document Detail

Anti-VEGF Strategies - from Antibodies to Tyrosine Kinase Inhibitors: Background and Clinical Development in Human Cancer.
MedLine Citation:
PMID:  22390756     Owner:  NLM     Status:  Publisher    
Tumor angiogenesis (formation of new blood vessels supporting tumour growth and metastasis) is a result of complex interactions between the tumour and the surrounding microenvironment. Targeting tumours with anti-angiogenic therapy remains an exciting area of preclinical and clinical studies. Although many significant advances have been achieved and the clinical use of anti-angiogenic drugs is now well recognized in many solid malignancies, these therapies fall short of their anticipated clinical benefits and leave many unanswered questions like exact mechanism of action, patients' selection and monitoring response to anti-angiogenic drugs. Tumour angiogenesis is controlled by complex signaling cascades and ongoing research into molecular mechanisms of tumour angiogenesis not only helps to understand its basic mechanisms but hopefully will identify new therapeutic targets. In 2012, both monoclonal antibodies and small molecule tyrosine kinase inhibitors remain the two major clinically useful therapeutic options that interfere with tumour angiogenesis in many solid malignancies.
Grzegorz Korpanty; Elizabeth Smyth
Related Documents :
24338366 - Plasma membrane translocation of redd1 governed by gpcrs contributes to mtorc1 activation.
23673666 - Identification of canonical tyrosine-dependent and non-canonical tyrosine-independent s...
23614736 - Potential role of foxo1 and mtorc1 in the pathogenesis of western diet-induced acne.
24249046 - Mir-451 downregulates neutrophil chemotaxis via p38 mitogen-activated protein kinase.
2981556 - Specific substrate for histone kinase ii: a synthetic nonapeptide.
2164806 - Effect of genistein, a tyrosine kinase inhibitor, on u46619-induced phosphoinositide ph...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-2-28
Journal Detail:
Title:  Current pharmaceutical design     Volume:  -     ISSN:  1873-4286     ISO Abbreviation:  -     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-3-6     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9602487     Medline TA:  Curr Pharm Des     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Medical Oncology, Beaumont Hospital, Dublin, Ireland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Targeting the EGFR-family for Therapy: Biological Challenges and Clinical Perspective.
Next Document:  Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer.